A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors

  1. Nina C. Lindfors1,*,
  2. Ilona Koski2,
  3. Jouni T. Heikkilä3,
  4. Kimmo Mattila2,
  5. Allan J. Aho3

Article first published online: 14 APR 2010

DOI: 10.1002/jbm.b.31636

Issue

Journal of Biomedical Materials Research Part B: Applied Biomaterials

Journal of Biomedical Materials Research Part B: Applied Biomaterials

Volume 94B, Issue 1, pages 157–164, July 2010

Additional Information

How to Cite

Lindfors, N. C., Koski, I., Heikkilä, J. T., Mattila, K. and Aho, A. J. (2010), A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J. Biomed. Mater. Res., 94B: 157–164. doi: 10.1002/jbm.b.31636

Author Information

  1. 1

    Helsinki University Central Hospital, Department of Orthopedic and Hand Surgery, Helsinki University, Helsinki, Finland

  2. 2

    Turku University Hospital and Medical Imaging Center of Southwest Finland, Turku, Finland

  3. 3

    The Biomaterial Project of Turku, Department of Orthopedic and Traumatology, Turku University Hospital, Turku, Finland

*Helsinki University Central Hospital, Department of Orthopedic and Hand Surgery, Helsinki University, Helsinki, Finland

Publication History

  1. Issue published online: 2 JUN 2010
  2. Article first published online: 14 APR 2010
  3. Manuscript Accepted: 26 JAN 2010
  4. Manuscript Revised: 25 JAN 2010
  5. Manuscript Received: 9 OCT 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1427K)

Keywords:

  • bioactive glass;
  • bone substitute;
  • biocompatibility/hard tissue

Abstract

A prospective randomized long-term follow-up study of bioactive glass (BG)-S53P4 and autogenous bone (AB) used as bone graft substitutes in benign bone tumor surgery during 1993–1997 was conducted. Twenty-one patients (11 in the BG group, 10 in the AB group) participated in a 14-year follow-up. X-rays and MRI scans were obtained, and in the BG group, CT scans were also performed. In the BG group, the filled cavity had a dense appearance on X-ray. MRI showed a mainly or partly fatty bone marrow, and in the large bone tumor group, remnants of glass granules were also observed. Increased cortical thickness was seen in nonossifying fibromas and enchondromas. BG-S53P4 is a safe and well-tolerated bone substitute with good long-term results. BG-S53P4 does not disturb the growth of bone in children. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2010.

View Full Article (HTML) Get PDF (1427K)